Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area
D2.191 - Tolerogenic Immune Shifts Following PQ Grass 27600 SU Treatment in Seasonal Allergic Rhinitis
D2.181 - Managing asthma and allergies during the Russo-Ukrainian war: The damage assessment
D2.183 - Differential Sensitization to Goat and Sheep Milk with Partial Tolerance to Cow’s Milk
D2.184 - Sensitization profile to vespid venom: limitations in clinical practice
D2.187 - Are Component-Based Skin Tests Reliable? Correlation between Skin Prick Testing and Specific IgE to Der p 1, Der p 2 and Der p 23
D2.188 - Spectrum of Sensitization to Respiratory Allergens in Patients in the Republic of Kazakhstan
D2.190 - Evaluation of a commercially available Birch Pollen Extract for its suitability in Nasal Allergen Challenges: Feasibility and Dose-Response Assessment
D2.192 - Comparison of the Multiplex ALEX Method and Single-Plex ImmunoCAP Method in the Diagnosis of Seasonal Allergic Rhinitis in Adults Caused by Birch Pollen
D2.193 - Real-World Effectiveness of Allergen Immunotherapy in Polysensitized Patients: A Retrospective Study of 260 Cases
D2.195 - AIT prescription drivers: a cluster analysis of data from the CHOICE survey
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download